- Avelumab, sold
under the
brand name
Bavencio, is a
fully human monoclonal antibody medication for the
treatment of
Merkel cell carcinoma,
urothelial carcinoma...
- Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive,
Erbitux and
Bavencio Revenue USD ~5
billion (projected)
Website www.merckserono.com www.emdserono...
- cell lung cancer,
hepatocellular carcinoma,
metastatic melanoma Avelumab Bavencio Merck KGaA and
Pfizer PD-L1 2017
Merkel cell carcinoma,
urothelial carcinoma...
- (CLL)
Atezolizumab Tecentriq humanized PD-L1 2016
bladder cancer Avelumab Bavencio human PD-L1 2017
metastatic Merkel cell
carcinoma Ipilimumab Yervoy human...
-
atezolizumab for
urothelial carcinoma and non-small cell lung cancer.
Avelumab (
Bavencio) is a
fully human IgG1
antibody developed by
Merck Serono and Pfizer. Avelumab...
-
Rhesus factor hemolytic disease of the newborn[citation needed]
Avelumab Bavencio mab
human PD-L1 Y
cancer Azintuxizumab vedotin mab chimeric/ humanized...
-
Urothelial carcinoma Metastatic non-small cell lung
cancer 761041 Link
avelumab Bavencio EMD
Serono 3/23/2017
intravenous fully human PD-L1
Metastatic Merkel cell...
- 2014. The
checkpoint is also the
target of EMD
Serono (Merck KGaA)'s drug
Bavencio,
which gained FDA
approval in 2017. An
advantage of
targeting PD-1 is that...
